Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics' stock price has increased significantly, reaching $91.56 as of November 21, 2025, a 355.52% increase from the previous year. The 52-week high is $105.00. Recently, the stock gapped up but later traded down. The company reported third-quarter 2025 financial results with earnings per share of ($0.48), missing analysts' estimates. Analyst sentiment is generally positive, with a "Buy" rating and a target price of $106.20. Tactic Pharma sold a significant portion of its shares, while institutional investors increased their positions. The winding down of previous programs has impacted the stock price.

There is no information available regarding demand seasonality for Monopar Therapeutics Inc.'s products and services. Revenue generation is typically tied to drug development milestones, regulatory approvals, and eventual commercialization, rather than seasonal consumer demand.

Monopar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and rare diseases, operating within the Biotechnology and Pharmaceutical industry. Its pipeline includes radiopharmaceuticals for oncology, such as MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac, as well as ALXN1840 for Wilson Disease. The company previously wound down its Validive and Camsirubicin programs.

Monopar Therapeutics Inc. is headquartered in Wilmette, Illinois, United States. Clinical studies for MNPR-101-Zr and MNPR-101-Lu have entered Phase 1 in Australia, and an Expanded Access Program is open for enrollment in Houston, Texas.

The provided search results do not contain specific information or events that have significantly impacted Monopar Therapeutics Inc.'s brand reputation in the past year. No particular events affecting its reputation were detailed.

Monopar Therapeutics Inc. has a mix of institutional and individual ownership. Institutional owners hold between 3,468,921 and 4,503,888 shares, representing approximately 31% to 1.83% of the stock. Major institutional shareholders include Janus Henderson Group Plc, Adage Capital Partners Gp, L.l.c., and Ra Capital Management, L.p.. Individual investors own 32% of the company, and insiders collectively own US$26 million worth. Hedge funds control about 8.3% of the shares.